logo

MANGALAM vs ORCHPHARMA: Stock Comparison

MANGALAM DRUG & CHEM vs ORCHID PHARMAUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

ORCHID PHARMA is the larger company by market capitalisation. ORCHID PHARMA shows a higher ROE, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

MANGALAM leads 0; ORCHPHARMA leads 7 of 11

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

MANGALAMORCHPHARMA

Valuation lens

What price are you paying?

Market CapContext only
₹47 Cr
₹5,233 Cr
P/E RatioSame reading
—
414.15x
P/B RatioSame reading
—
2.83x
EPSORCHPHARMA has the higher reading
₹-4.83
₹0.64 ✓
Book ValueContext only
₹65.11
₹308.43
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
ORCHPHARMA is the larger company
₹5,233 Cr vs ₹47 Cr
EPS
ORCHPHARMA has higher earnings per share
₹0.64 vs ₹-4.83
Revenue Growth (TTM YoY)
ORCHPHARMA has faster revenue growth
-1.5% vs -7.5%
ROE
ORCHPHARMA has a higher ROE
1.58% vs -42.41%
ROCE
ORCHPHARMA has a higher ROCE
2.09% vs -15.52%
Net Margin
ORCHPHARMA has a higher net margin
2.51% vs -19.13%
Operating Margin
ORCHPHARMA has a higher operating margin
4.22% vs -13.69%
Debt to Equity
ORCHPHARMA has lower leverage
0.28x vs 0.99x

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricMANGALAMORCHPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricMANGALAMORCHPHARMA
Live Price₹29.57₹875.55
Day Change-2.79%-1.28%
Volume11,15752,511
52-Week High₹71.99₹1,143.5
52-Week Low₹22.8₹480
Distance from 52W High-58.92%-23.43%

Valuation

MetricMANGALAMORCHPHARMA
Market Cap₹47 Cr₹5,233 Cr
P/E Ratio—414.15x
P/B Ratio—2.83x
EPS₹-4.83₹0.64
Book Value₹65.11₹308.43
Dividend Yield0%0%

Growth

MetricMANGALAMORCHPHARMA
Revenue Growth (TTM YoY)-7.5%-1.5%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricMANGALAMORCHPHARMA
ROE-42.41%1.58%
ROCE-15.52%2.09%
Net Margin-19.13%2.51%
Operating Margin-13.69%4.22%
Debt to Equity0.99x0.28x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricMANGALAMORCHPHARMA
Promoter Holding35.65%74.45%▲ 4.61 pp
FII Holding0.11%0.93%▲ 0.12 pp
DII Holding0%17.44%▼ 3.31 pp
Public Holding64.24%7.18%▼ 1.43 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: MANGALAM DRUG & CHEM and ORCHID PHARMA.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.